Review article · 2021 · Open access
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Molecular Neurodegeneration, 16(1), 10 · Published 19 February 2021 · DOI 10.1186/s13024-021-00430-x
In brief
“Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics” is a 2021 review article by Henrik Zetterberg and Kaj Blennow, published in Molecular Neurodegeneration. OpenAlex counts 241 citations as of 18 November 2026, which puts it in the top 1% of works published in 2021 by citations. It is open access under a CC BY licence: the full text is free to read at Molecular Neurodegeneration.
- Citations
- 241
- Most cited in
- 2022 (51)
- Field-weighted impact
- 4.88
- References
- 64
- Authors
- 2
Abstract
Four fluid-based biomarkers have been developed into diagnostic tests for Alzheimer's disease (AD) pathology: the ratio of 42 to 40 amino acid-long amyloid β, a marker of plaque pathology; total-tau and phosphorylated tau, markers of AD-related changes in tau metabolism and secretion; and neurofilament light, a marker of neurodegeneration. When measured in cerebrospinal fluid, these biomarkers can be used in clinical practice to support a diagnosis of mild cognitive impairment or dementia due to AD. Recently, technological breakthroughs have made it possible to measure them in standard blood samples as well. Here, we give an updated account of the current state of the fluid-based AD biomarker research field. We discuss how the new blood tests may be used in research and clinical practice, and what role they may play in relation to more established diagnostic tests, such as CSF biomarkers and amyloid and tau positron emission tomography, to facilitate the effective implementation of future disease-modifying therapies.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Zetterberg, H., & Blennow, K. (2021). Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics. Molecular Neurodegeneration, 16(1), 10. https://doi.org/10.1186/s13024-021-00430-x
MLA 9
Zetterberg, Henrik, and Kaj Blennow. “Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics.” Molecular Neurodegeneration, vol. 16, no. 1, 2021, p. 10. https://doi.org/10.1186/s13024-021-00430-x.
Chicago
Zetterberg, Henrik and Kaj Blennow. 2021. “Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics.” Molecular Neurodegeneration 16 (1): 10. https://doi.org/10.1186/s13024-021-00430-x.
Harvard
Zetterberg, H. and Blennow, K. (2021) ‘Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics’, Molecular Neurodegeneration, 16(1), p. 10. doi:10.1186/s13024-021-00430-x.
IEEE
H. Zetterberg and K. Blennow, “Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics,” Molecular Neurodegeneration, vol. 16, no. 1, p. 10, 2021, doi: 10.1186/s13024-021-00430-x.
BibTeX
@article{zetterberg2021moving,
title = {{Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics}},
author = {Zetterberg, Henrik and Blennow, Kaj},
journal = {Molecular Neurodegeneration},
year = {2021},
volume = {16},
number = {1},
pages = {10},
doi = {10.1186/s13024-021-00430-x},
url = {https://doi.org/10.1186/s13024-021-00430-x}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2021 | 18 | |
| 2022 | 51 | |
| 2023 | 34 | |
| 2024 | 42 | |
| 2025 | 50 | |
| 2026 | 46 |
Its field-weighted citation impact is 4.88: it has been cited 4.88 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Alzheimer's disease
- fluid biomarkers
- amyloid-beta 42/40 ratio
- total tau
- phosphorylated tau
- neurofilament light chain
- cerebrospinal fluid biomarkers
- blood-based biomarkers
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Zetterberg, H., & Blennow, K. (2021). Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics. Molecular Neurodegeneration, 16(1), 10. https://doi.org/10.1186/s13024-021-00430-x
How many times has this paper been cited?
241 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Molecular Neurodegeneration: sign in and open the PDF from this page.
Who wrote this paper?
Henrik Zetterberg, Kaj Blennow.
What is the DOI of this paper?
10.1186/s13024-021-00430-x, permanently at https://doi.org/10.1186/s13024-021-00430-x. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.